Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309

Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,030

IL-23 promotes tumour incidence and growth

Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820

Gene expression markers of Tumor Infiltrating Leukocytes

Danaher, P. J., Warren, S. E., Dennis, L. M., D’Amico, L., White, A. M., Disis, M. L., Geller, M. A., Odunsi, K. O., Beechem, J., & Fling, S. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0215-8 · Cited by 792

Discovery and Biology of IL-23 and IL-27: Related but Functionally Distinct Regulators of Inflammation

Kastelein, R. A., Hunter, C. A., & Cua, D. J. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104758 · Cited by 777

Professional Antigen-Presentation Function by Human γδ T Cells

Brandes, M., Willimann, K., & Moser, B. (2005) · Science · doi:10.1126/science.1110267 · Cited by 769

IL‐12 and IL‐23: master regulators of innate and adaptive immunity

Langrish, C. L., McKenzie, B. S., Wilson, N. J., Malefyt, R. D. W., Kastelein, R. A., & Cua, D. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00214.x · Cited by 749

The significance of OX40 and OX40L to T‐cell biology and immune disease

Croft, M., So, T., Duan, W., & Soroosh, P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00766.x · Cited by 628

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 528

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

Curti, B. D., Kovacsovics-Bankowski, M., Morris, N. P., Walker, E., Chisholm, L., Floyd, K., Walker, J. M., Gonzalez, I. L., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 503

Targeting T Cell Co-receptors for Cancer Therapy

Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 480

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0114 · Cited by 422

IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

Stritesky, G. L., Yeh, N., & Kaplan, M. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.5948 · Cited by 417

High Avidity CTLs for Two Self-Antigens Demonstrate Superior In Vitro and In Vivo Antitumor Efficacy

Zeh, H. J., Perry-Lalley, D. M., Dudley, M. E., Rosenberg, S. A., & Yang, J. C.-H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.2.989 · Cited by 377

Th17 Cells in Cancer: The Ultimate Identity Crisis

Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 358

Eradication of spontaneous malignancy by local immunotherapy

Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 357

TLR agonists: our best frenemy in cancer immunotherapy

Kaczanowska, S., Joseph, A. M., & Dávila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 352

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

Lechner, M. G., Karimi, S. S., Barry-Holson, K. Q., Angell, T. E., Murphy, K. A., Church, C. H., Ohlfest, J. R., Hu, P., & Epstein, A. L. (2013) · Journal of Immunotherapy · doi:10.1097/01.cji.0000436722.46675.4a · Cited by 351

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T., Grimm, M., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 334

IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin

Foster, A. M., Baliwag, J., Chen, C. S., Guzman, A. M., Stoll, S. W., Gudjonsson, J. E., Ward, N. L., & Johnston, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301481 · Cited by 303

IL ‐17‐producing γδ T cells and innate lymphoid cells

Sutton, C. E., Mielke, L. A., & Mills, K. H. G. (2012) · European Journal of Immunology · doi:10.1002/eji.201242569 · Cited by 289

IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells

Belladonna, M. L., Renauld, J., Bianchi, R., Vacca, C., Fallarino, F., Orabona, C., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5448 · Cited by 232

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

Aznar, M. A., Tinari, N., Rullan, A., Sánchez-Paulete, A. R., Rodriguez-Ruiz, M. E., & Melero, I. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601145 · Cited by 229

Regulation and function of interleukin‐36 cytokines

Bassoy, E. Y., Towne, J. E., & Gabay, C. (2017) · Immunological Reviews · doi:10.1111/imr.12610 · Cited by 198

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164

Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo

Lieschke, G. J., Rao, P. K., Gately, M. K., & Mulligan, R. C. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-35 · Cited by 154

Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells

Chan, I. H., JAIN, R. K., Tessmer, M. S., Gorman, D., Mangadu, R., Sathe, M., Vives, F., Moon, C., Penaflor, E., Turner, S. P., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.101 · Cited by 145

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130

IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses

Wang, X., Zhao, X., Feng, C., Weinstein, A. M., Xia, R., Wen, W., Lv, Q., Zuo, S., Tang, P., Yang, X., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.014 · Cited by 123

A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage

Ngo, V. L., Abo, H., Maxim, E., Harusato, A., Geem, D., Contreras, O. M., Merlin, D., Gewirtz, A. T., Nusrat, A., & Denning, T. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718902115 · Cited by 123

The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review

Punt, S., Langenhoff, J. M., Putter, H., Fleuren, G. J., Gorter, A., & Jordanova, E. S. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.984547 · Cited by 122

A balance of interleukin-12 and -23 in cancer

Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.004 · Cited by 117

Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα

Choi, I.-K., Lee, J.-S., Zhang, S.-N., Park, J. H., Lee, K.-M., Sonn, C. H., & Yun, C.-O. (2011) · Gene Therapy · doi:10.1038/gt.2011.37 · Cited by 107

Targeting Costimulatory Molecules to Improve Antitumor Immunity

Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · BioMed Research International · doi:10.1155/2012/926321 · Cited by 103

Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-12

Kaiga, T., Sato, M., Kaneda, H., Iwakura, Y., Takayama, T., & Tahara, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.12.7571 · Cited by 97

Different Members of the IL-1 Family Come Out in Different Ways: DAMPs vs. Cytokines?

Carta, S., Lavieri, R., & Rubartelli, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00123 · Cited by 90

Regulation and function of IL-17A- and IL-22-producing γδ T cells

Ness-Schwickerath, K. J., & Morita, C. T. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0700-z · Cited by 79

Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity

Jensen, S. S., & Gad, M. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-37 · Cited by 72

Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic

Majchrzak, K., Nelson, M. H., Bailey, S. R., Bowers, J. S., Yu, X., Rubinstein, M. P., Himes, R. A., & Paulos, C. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1797-6 · Cited by 48

Common gamma chain cytokines in combinatorial immune strategies against cancer

Pulliam, S. R., Uzhachenko, R. V., Adunyah, S. E., & Shanker, A. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.11.007 · Cited by 46

Parallels and differences between innate and adaptive lymphocytes

Bedoui, S., Gebhardt, T., Gasteiger, G., & Kastenmüller, W. (2016) · Nature Immunology · doi:10.1038/ni.3432 · Cited by 46

The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes

Wallace, A. F., LaRosa, D. F., Kapoor, V., Sun, J., Cheng, G., Jassar, A. S., Blouin, A., Ching, L., & Albelda, S. Μ. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3757 · Cited by 44

The Dichotomous Pattern of IL-12R and IL-23R Expression Elucidates the Role of IL-12 and IL-23 in Inflammation

Chognard, G., Bellemare, L., Pelletier, A., Domínguez-Punaro, M. D. L. C., Beauchamp, C., Guyon, M.-J., Charron, G., Morin, N., Sivanesan, D., Kuchroo, V. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089092 · Cited by 43

IL-1 family cytokines in cancer immunity – a matter of life and death

Mora, J., & Weigert, A. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0215 · Cited by 25

Decreased expression of interleukin-36α predicts poor prognosis in colorectal cancer patients.

Wang, Z., Cong, Z., Luo, Y., Mu, Y., Qin, S., Zhong, M., & Chen, J. (2014) · Europe PMC (PubMed Central) · Cited by 23

Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity

Gürlevik, E., Woller, N., Strüver, N., Schache, P., Kloos, A., Manns, M. P., Zender, L., Kühnel, F., & Kubicka, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.163 · Cited by 23

Messenger RNA as a Novel Therapeutic Approach

Stanton, M. G., & Murphy-Benenato, K. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_30 · Cited by 16

Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA

Wang, J., Kobayashi, Y., Sato, A., Kobayashi, E., & Murakami, T. (2004) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2004.08.001 · Cited by 14

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076

mRNA vaccine for cancer immunotherapy

Miao, L., Zhang, Y., & Huang, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01335-5 · Cited by 966

Enhancing cancer immunotherapy with nanomedicine

Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 908

Interleukins in cancer: from biology to therapy

Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00363-z · Cited by 822

Nanodelivery of nucleic acids

Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719

Abstract 1607: Durable efficacy and anti-cancer immunity following intratumoral administration of messenger RNAs encoding IL-36γ, IL-23 and OX40L

Frederick, J. P., Bai, A., Hewitt, S. L., Karp, R., Zielinski, J. F., Ichikawa, K., Apte, A., Bailey, D., Arnold, K., Farlow, S., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-1607 · Cited by 1

Abstract 1711: Induction of anti-tumor immunity by intratumoral delivery of mRNA encoding cytokines and TNFRSF agonists

Gavigan, J.-A., Shi, C., Lampa, M., Malkova, N. V., Yu, Q., Qu, H., Levit, M. N., Wagenaar, T. R., Hotz, C., & Li, X. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1711 · Cited by 2

Immune checkpoint blockade combined with IL ‐6 and TGF ‐β inhibition improves the therapeutic outcome of m RNA ‐based immunotherapy

Bialkowski, L., der Jeught, K. V., Bevers, S., Joe, P. T., Renmans, D., Heirman, C., Aerts, J. L., & Thielemans, K. (2018) · International Journal of Cancer · doi:10.1002/ijc.31331 · Cited by 38

Abstract CT210: A Phase I, open-label, multicenter, dose escalation study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral injection alone and in combination with immune checkpoint blockade

Bauer, T. M., Patel, M. R., Jimeno, A., Wang, D., McDermott, J. D., Zacharek, S. J., Randolph, W., Johansen, L. M., Hopson, K., Frederick, J. P., et al. (2019) · Clinical Trials · doi:10.1158/1538-7445.sabcs18-ct210

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells

Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130